Skip to main content

Table 1 DHMEQ-mediated sensitizing effect to anticancer agents in T24 and T24PR cells

From: Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer

anticancer agents T24 T24PR combination with DHMEQ (3 μg/ml) in T24PR
IC50 ± SE IC50 ± SE RF IC50 ± SE CI
cisplatin(μM) 4.5 ± 0.1 27 ± 1.5 5.9 9.8 ± 0.6 0.75
gemcitabine(nM) 231 ± 25 910 ± 33 3.9 124 ± 5.1 0.71
paclitaxel(nM) 49 ± 1.8 62 ± 2.6 1.3 20 ± 1.1 0.79
carboplatin(μM) 65 ± 2.8 208 ± 9.8 3.2 75 ± 5.5 0.74
  1. Abbreviation: RF = resistance factor, CI = combination index.